⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL311557 | 0.96 | — | — | |
| Dimethylamine SCHEMBL28252531 | 0.86 | — | — | |
| SCHEMBL298778 | 0.85 | — | — | |
| SCHEMBL519 | 0.85 | — | — | |
| SCHEMBL1331666 | 0.85 | — | — | |
| SCHEMBL1331921 | 0.85 | — | — | |
| SCHEMBL1331275 | 0.85 | — | — | |
| SCHEMBL5180151 | 0.85 | — | — | |
| SCHEMBL11026359 | 0.85 | — | — | |
| Dimethylamine SCHEMBL28842897 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111808011-B | High penetration composition and its application | 泰飞尔生物医药(苏州)有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20230233516-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | TECHFIELDS PHARMA CO., LTD (CN) | 2023-07-27 | — | — | US | disclosed |
| US-11541029-B2 | High penetration compositions and their applications | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| CN-113636965-A | High penetration composition and application thereof | 于崇曦 | 2021-11-12 | — | — | CN | disclosed |
| CN-107320732-B | High penetration composition and application thereof | 于崇曦 | 2021-09-07 | — | — | CN | disclosed |
| CN-108191846-B | High penetration composition and application thereof | 于崇曦 | 2021-08-20 | — | — | CN | disclosed |
| CN-111808011-A | High penetration composition and application thereof | 于崇曦 | 2020-10-23 | — | — | CN | disclosed |
| US-20130178462-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-11 | — | — | US | disclosed |
| US-8071768-B2 | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20110269689-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2011-11-03 | — | — | US | disclosed |
| US-7115640-B2 | Heterocyclic modulators of nuclear receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-6894047-B2 | Triazine compounds useful as sorbitol dehydrogenase inhibitors | PFIZER INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20040180942-A1 | Heterocyclic modulators of nuclear receptors | X-CEPTOR THERAPEUTICS, INC. | 2004-09-16 | — | — | US | disclosed |
| US-6710185-B2 | REACTING N-FORMYLINDOLINE WITH CHLOROSULFONIC ACID AND THIONYL CHLORIDE; AND REACTING THE PRODUCT WITH SODIUM BICARBONATE AND AN ANILINE COMPOUND | ABBOTT LABORATORIES | 2004-03-23 | — | — | US | disclosed |
| US-6696473-B2 | THIAZOLIDINONE DERIVATIVES; MODULATING CHOLESTEROL METABOLISM | X-CEPTOR THERAPEUTICS, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030212111-A1 | Heterocyclic modulators of nuclear receptors | AKARNA THERAPEUTICS, LTD. (GB) | 2003-11-13 | — | — | US | disclosed |
| US-20030078439-A1 | Process for the preparation of cell proliferation inhibitors | ABBVIE INC. | 2003-04-24 | — | — | US | disclosed |
| US-20030004166-A1 | Novel triazine compounds useful as sorbitol dehydrogenase inhibitors | PFIZER INC. | 2003-01-02 | — | — | US | disclosed |
| EP-1247809-A2 | Triazine compounds useful as sorbitol dehydrogenase inhibitors | Pfizer Products Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2002024648-A2 | PROCESS FOR THE PREPARATION OF CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |